DK1997481T3 - Solid oral form of a medical composition and method of preparation thereof - Google Patents
Solid oral form of a medical composition and method of preparation thereof Download PDFInfo
- Publication number
- DK1997481T3 DK1997481T3 DK06799634.8T DK06799634T DK1997481T3 DK 1997481 T3 DK1997481 T3 DK 1997481T3 DK 06799634 T DK06799634 T DK 06799634T DK 1997481 T3 DK1997481 T3 DK 1997481T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- dilution
- solid oral
- drug
- aqueous
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 239000007787 solid Substances 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 6
- 238000010790 dilution Methods 0.000 claims description 37
- 239000012895 dilution Substances 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 27
- 230000001632 homeopathic effect Effects 0.000 claims description 15
- 230000009471 action Effects 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RVCMQOUQLRUENR-XSFUTMHBSA-N 4-[[(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl]oxy]-4-oxobutanoic acid Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(=O)CCC(O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O RVCMQOUQLRUENR-XSFUTMHBSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2006107580/15A RU2309732C1 (ru) | 2006-03-13 | 2006-03-13 | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| PCT/RU2006/000237 WO2007105981A1 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1997481T3 true DK1997481T3 (en) | 2017-12-11 |
Family
ID=38509730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06799634.8T DK1997481T3 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medical composition and method of preparation thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9522116B2 (enExample) |
| EP (1) | EP1997481B1 (enExample) |
| JP (1) | JP5551429B2 (enExample) |
| KR (1) | KR20080109017A (enExample) |
| CN (1) | CN101415403B (enExample) |
| AU (1) | AU2006340119B2 (enExample) |
| BR (1) | BRPI0621507A2 (enExample) |
| CA (1) | CA2645475C (enExample) |
| CY (1) | CY1119682T1 (enExample) |
| DK (1) | DK1997481T3 (enExample) |
| EA (1) | EA200801971A1 (enExample) |
| ES (1) | ES2651350T3 (enExample) |
| HU (1) | HUE035265T2 (enExample) |
| LT (1) | LT1997481T (enExample) |
| MX (1) | MX2008011811A (enExample) |
| PL (1) | PL1997481T3 (enExample) |
| PT (1) | PT1997481T (enExample) |
| RU (1) | RU2309732C1 (enExample) |
| UA (1) | UA92076C2 (enExample) |
| WO (1) | WO2007105981A1 (enExample) |
| ZA (1) | ZA200808631B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| CA2654408C (en) | 2006-06-06 | 2018-05-08 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| RU2525156C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии |
| RU2523557C2 (ru) * | 2010-07-15 | 2014-07-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии |
| RU2531048C2 (ru) * | 2010-07-21 | 2014-10-20 | Мапикс Эс.Эй.Ар.Эл. | Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами |
| RU2525155C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности |
| RU2542453C2 (ru) * | 2010-07-21 | 2015-02-20 | Олег Ильич Эпштейн | Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов |
| MX2013000543A (es) | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| FR2962652A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| RU2522499C2 (ru) * | 2010-07-27 | 2014-07-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способ лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями |
| EA029400B1 (ru) * | 2010-07-15 | 2018-03-30 | Олег Ильич ЭПШТЕЙН | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения |
| RU2509573C2 (ru) * | 2010-07-27 | 2014-03-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза |
| PH12013500144A1 (en) | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| RU2528093C2 (ru) * | 2010-07-21 | 2014-09-10 | Олег Ильич Эпштейн | Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля |
| RU2535033C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| CZ2013159A3 (cs) * | 2010-08-06 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| GB2566200A (en) * | 2016-05-17 | 2019-03-06 | Iliich Epshtein Oleg | A pharmaceutical composition that includes a neutral carrier treated with energy and related methods of treatment |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| RU2018118695A (ru) * | 2018-05-22 | 2019-11-22 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство для лечения нарушений функций органа или ткани, а также заболеваний, сопровождающихся данными нарушениями, и способ его получения |
| CN114375200A (zh) | 2019-08-29 | 2022-04-19 | 奥列格·伊利奇·爱泼斯坦 | 治疗传染病的药物和方法 |
| WO2025088452A1 (en) | 2023-10-24 | 2025-05-01 | Epshtein Oleg Ilyich | Artificial substance and method of its preparation |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901967A (en) * | 1973-09-10 | 1975-08-26 | Union Corp | Sustained release of atropine |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| JPS61176534A (ja) | 1985-01-30 | 1986-08-08 | Takashi Muramatsu | 避妊用剤 |
| US5066491A (en) * | 1985-04-15 | 1991-11-19 | Protein Technology, Inc. | Method of disease treatment utilizing an immunologically active whey fraction |
| FR2609895B1 (fr) | 1987-01-28 | 1991-06-28 | Bruttmann Georges | Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale |
| US5244663A (en) * | 1987-01-28 | 1993-09-14 | Medibrevex | Therapeutic method against allergy |
| JPH01252581A (ja) * | 1988-03-31 | 1989-10-09 | Taiyo Yuden Co Ltd | 窒化物セラミツクスの製造方法 |
| FI101344B1 (fi) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| RU2007989C1 (ru) | 1991-11-12 | 1994-02-28 | Акционерное общество "Трейдис" | Способ габович подбора гомеопатических препаратов и их разовой дозы |
| RU2035167C1 (ru) | 1992-07-16 | 1995-05-20 | Гальцев Юрий Викторович | Способ получения биологически активного водного раствора меда |
| JP3616091B2 (ja) * | 1992-10-08 | 2005-02-02 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| US5879677A (en) * | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
| WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| RU2033784C1 (ru) | 1993-05-28 | 1995-04-30 | Индивидуальное частное предприятие "Диалог" | Устройство для репродуцирования гомеопатических и изопатических препаратов |
| JPH073754A (ja) | 1993-06-17 | 1995-01-06 | Marsima Aqua Syst Corp | 魚道ゲート |
| IT1261849B (it) * | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| EP0725789B1 (en) * | 1993-09-20 | 2003-03-19 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
| NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| JP3696884B2 (ja) * | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
| IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
| PT854718E (pt) * | 1995-09-21 | 2004-08-31 | Pharma Pass Ii Llc | Composicao farmaceutica contendo um benzimidazole acido-labil e processo para a sua preparacao |
| RU2161481C2 (ru) | 1995-09-21 | 2001-01-10 | Фарма Пасс Ллс | Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения |
| AU723812B2 (en) | 1996-02-12 | 2000-09-07 | Oleg Iliich Epshtein | Medicinal preparation and a method of medicinal action on human organism |
| US5834443A (en) | 1996-05-21 | 1998-11-10 | Masiello; Domenick J. | Composition and method for treating herpes simplex |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| RU2132181C1 (ru) | 1996-09-30 | 1999-06-27 | Эпштейн Олег Ильич | Средство для воздействия на организм |
| RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
| RU2114605C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Защитная добавка для косметических средств |
| JPH10212246A (ja) * | 1997-01-30 | 1998-08-11 | Nippon Zoki Pharmaceut Co Ltd | 経口投与用製剤 |
| RU2103999C1 (ru) | 1997-01-31 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения алкоголизма |
| RU2104006C1 (ru) | 1997-02-14 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения наркомании |
| DE19746868A1 (de) | 1997-10-23 | 1999-04-29 | Knoll Ag | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
| RU2122858C1 (ru) | 1997-12-29 | 1998-12-10 | Яковлева Людмила Борисовна | Гомеопатическое лекарственное средство седативного действия "вернисон" |
| RU2133123C1 (ru) | 1997-12-29 | 1999-07-20 | Эпштейн Олег Ильич | Гомеопатическое лекарственное средство для лечения диспептических расстройств "нетизжог" |
| KR20010041696A (ko) * | 1998-03-11 | 2001-05-25 | 그레랑 파마수티컬 가부시키가이샤 | 발포성 장용(腸溶) 제제 |
| RU2187334C2 (ru) | 1998-05-22 | 2002-08-20 | Эпштейн Олег Ильич | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| JP2000302691A (ja) | 1999-02-17 | 2000-10-31 | Biomed Comm Inc | 精製成長ホルモンのホメオパシー調製剤 |
| RU2161955C1 (ru) | 1999-07-16 | 2001-01-20 | Эпштейн Олег Ильич | Способ изменения физико-химических или физико-химических и биологических свойств вещества |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2182008C1 (ru) * | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
| RU2182492C1 (ru) | 2000-12-14 | 2002-05-20 | Эпштейн Олег Ильич | Лекарственное средство для лечения наркотической зависимости |
| RU2191601C1 (ru) | 2001-04-18 | 2002-10-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эректильных дисфункций |
| RU2192882C1 (ru) | 2001-04-18 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
| RU2201254C1 (ru) * | 2001-09-25 | 2003-03-27 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| RU2209083C1 (ru) | 2001-12-26 | 2003-07-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения кашля |
| FR2836379B1 (fr) * | 2002-02-28 | 2007-06-01 | Dit Bon Michel Betend | Formes galeniques solides de medicaments homeopathiques, dont les allergenes ou antigenes, en dilutions homeopathiques pour preparation extemporanee pour un seul individu pour administration sublinguale |
| UA76641C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| UA76638C2 (en) * | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| RU2253478C1 (ru) | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
| RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| CA2654408C (en) * | 2006-06-06 | 2018-05-08 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| US20130189707A1 (en) * | 2010-01-26 | 2013-07-25 | Svetlana Alexandrovna Sergeeva | Method of determination of autoantibody level by means of enzyme immunoassay |
| MY157564A (en) * | 2010-07-15 | 2016-06-30 | Epshtein Oleg Lliich | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract |
| FR2962655A1 (fr) * | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire |
| EA029400B1 (ru) * | 2010-07-15 | 2018-03-30 | Олег Ильич ЭПШТЕЙН | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения |
| UA114699C2 (uk) * | 2010-07-15 | 2017-07-25 | Олєг Ільіч Епштейн | Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою |
| FR2962652A1 (fr) * | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| WO2012014078A2 (en) * | 2010-07-21 | 2012-02-02 | Olge Iliich Epshtein | Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
| WO2012010978A2 (en) * | 2010-07-21 | 2012-01-26 | Oleg Iliich Epshtein | A method of treating alzheimer's disease |
| CN103118707A (zh) * | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法 |
| FR2962909A1 (fr) * | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire |
| PH12013500144A1 (en) * | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| US20130058981A1 (en) * | 2010-07-21 | 2013-03-07 | Oleg Iliich Epshtein | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| RU2535034C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| RU2535033C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| RU2517084C2 (ru) * | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
| US20120263725A1 (en) * | 2010-08-06 | 2012-10-18 | Epshtein Oleg Iiiich | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV |
| CZ2013159A3 (cs) * | 2010-08-06 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob |
| US20130171161A1 (en) * | 2010-12-23 | 2013-07-04 | Oleg Iliich Epshtein | Method and composition for the treatment of diseases caused by or associated with hiv |
-
2006
- 2006-03-13 RU RU2006107580/15A patent/RU2309732C1/ru not_active IP Right Cessation
- 2006-05-16 CN CN2006800540501A patent/CN101415403B/zh not_active Expired - Fee Related
- 2006-05-16 LT LTEP06799634.8T patent/LT1997481T/lt unknown
- 2006-05-16 PT PT67996348T patent/PT1997481T/pt unknown
- 2006-05-16 KR KR1020087024607A patent/KR20080109017A/ko not_active Ceased
- 2006-05-16 BR BRPI0621507-6A patent/BRPI0621507A2/pt not_active IP Right Cessation
- 2006-05-16 EP EP06799634.8A patent/EP1997481B1/en not_active Not-in-force
- 2006-05-16 JP JP2009500312A patent/JP5551429B2/ja not_active Expired - Fee Related
- 2006-05-16 AU AU2006340119A patent/AU2006340119B2/en not_active Ceased
- 2006-05-16 CA CA2645475A patent/CA2645475C/en not_active Expired - Fee Related
- 2006-05-16 HU HUE06799634A patent/HUE035265T2/en unknown
- 2006-05-16 PL PL06799634T patent/PL1997481T3/pl unknown
- 2006-05-16 WO PCT/RU2006/000237 patent/WO2007105981A1/ru not_active Ceased
- 2006-05-16 UA UAA200812133A patent/UA92076C2/uk unknown
- 2006-05-16 MX MX2008011811A patent/MX2008011811A/es active IP Right Grant
- 2006-05-16 US US12/282,614 patent/US9522116B2/en not_active Expired - Fee Related
- 2006-05-16 ES ES06799634.8T patent/ES2651350T3/es active Active
- 2006-05-16 DK DK06799634.8T patent/DK1997481T3/en active
- 2006-05-16 EA EA200801971A patent/EA200801971A1/ru unknown
-
2008
- 2008-10-09 ZA ZA2008/08631A patent/ZA200808631B/en unknown
-
2016
- 2016-11-11 US US15/349,640 patent/US20170056499A1/en not_active Abandoned
-
2017
- 2017-12-12 CY CY20171101299T patent/CY1119682T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009530271A (ja) | 2009-08-27 |
| CA2645475C (en) | 2015-03-17 |
| JP5551429B2 (ja) | 2014-07-16 |
| AU2006340119B2 (en) | 2012-01-12 |
| CN101415403A (zh) | 2009-04-22 |
| CN101415403B (zh) | 2013-07-10 |
| MX2008011811A (es) | 2009-02-06 |
| UA92076C2 (uk) | 2010-09-27 |
| CY1119682T1 (el) | 2018-04-04 |
| ES2651350T3 (es) | 2018-01-25 |
| PT1997481T (pt) | 2017-12-18 |
| WO2007105981A1 (en) | 2007-09-20 |
| AU2006340119A1 (en) | 2007-09-20 |
| US9522116B2 (en) | 2016-12-20 |
| RU2309732C1 (ru) | 2007-11-10 |
| EA200801971A1 (ru) | 2009-02-27 |
| EP1997481B1 (en) | 2017-09-13 |
| HUE035265T2 (en) | 2018-05-02 |
| PL1997481T3 (pl) | 2018-02-28 |
| LT1997481T (lt) | 2018-02-12 |
| US20170056499A1 (en) | 2017-03-02 |
| KR20080109017A (ko) | 2008-12-16 |
| US20090148521A1 (en) | 2009-06-11 |
| ZA200808631B (en) | 2009-12-30 |
| EP1997481A1 (en) | 2008-12-03 |
| CA2645475A1 (en) | 2007-09-20 |
| BRPI0621507A2 (pt) | 2011-12-13 |
| EP1997481A4 (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1997481T3 (en) | Solid oral form of a medical composition and method of preparation thereof | |
| AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| US8168182B2 (en) | Method for treating erectile dysfunction | |
| US8637030B2 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| US20110008452A1 (en) | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance | |
| US8987206B2 (en) | Method of treating attention deficit hyperactivity disorder | |
| CN103119060A (zh) | 治疗阿尔兹海默病的方法 | |
| RU2500427C2 (ru) | Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта | |
| RU2437678C2 (ru) | Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения | |
| RU2532323C2 (ru) | Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника | |
| RU2542414C2 (ru) | Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций | |
| RU2651005C2 (ru) | Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция |